EU finds J&J covid shot possibly linked to another rare clotting condition

Oct 1 (Reuters) – The European Union’s drug regulator on Friday identified a possible link between rare cases of blood clotting in deep veins with Johnson & Johnson’s (JNJ.N) COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot.

The European Medicines Agency also recommended that immune thrombocytopenia (ITP), a bleeding disorder caused by the body mistakenly attacking platelets, be added as an adverse reaction with an unknown frequency to the J&J vaccine product information and to AstraZeneca’s (AZN.L) vaccine.

www.reuters.com/business/healthcare-pharmaceuticals/eu-finds-jj-covid-shot-possibly-linked-another-rare-clotting-condition-2021-10-01/